These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14996620)

  • 1. Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.
    Nicolau DP
    Expert Opin Pharmacother; 2004 Feb; 5(2):229-35. PubMed ID: 14996620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D; Zhanel G; Hoban D
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
    Clark JP; Langston E
    Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic rationale for short-duration antibacterial therapy.
    Nicolau DP
    J Infect; 2002 Feb; 44 Suppl A():17-23. PubMed ID: 12150491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Telithromycin, a once-a-day ketolide in the treatment of community acquired pneumonia].
    Carbon C
    Presse Med; 2000 Dec; 29(37):2042-3. PubMed ID: 11155730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
    Hammerschlag MR; Roblin PM; Bébéar CM
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telithromycin (Ketek) for community-acquired respiratory tract infections.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
    [No Abstract]   [Full Text] [Related]  

  • 15. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin.
    Spiers KM; Zervos MJ
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials.
    Li XM; Wang FC; Yang F; Jin YH
    Chin Med J (Engl); 2013; 126(11):2179-85. PubMed ID: 23769580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
    Felmingham D; Farrell DJ; Reinert RR; Morrissey I
    J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safeguarding future antimicrobial options: strategies to minimize resistance.
    Leclercq R
    Clin Microbiol Infect; 2001; 7 Suppl 3():18-23. PubMed ID: 11523557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telithromycin (Ketek) for respiratory infections.
    Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.